207 related articles for article (PubMed ID: 18044731)
21. In vivo imaging of immunotoxin treatment using Katushka-transfected A-431 cells in a murine xenograft tumour model.
Pardo A; Stöcker M; Kampmeier F; Melmer G; Fischer R; Thepen T; Barth S
Cancer Immunol Immunother; 2012 Oct; 61(10):1617-26. PubMed ID: 22350071
[TBL] [Abstract][Full Text] [Related]
22. An anti-PSMA bivalent immunotoxin exhibits specificity and efficacy for prostate cancer imaging and therapy.
Zhang F; Shan L; Liu Y; Neville D; Woo JH; Chen Y; Korotcov A; Lin S; Huang S; Sridhar R; Liang W; Wang PC
Adv Healthc Mater; 2013 May; 2(5):736-44. PubMed ID: 23184611
[TBL] [Abstract][Full Text] [Related]
23. In vitro and in vivo cytotoxic activities of recombinant immunotoxin 8H9(Fv)-PE38 against breast cancer, osteosarcoma, and neuroblastoma.
Onda M; Wang QC; Guo HF; Cheung NK; Pastan I
Cancer Res; 2004 Feb; 64(4):1419-24. PubMed ID: 14973056
[TBL] [Abstract][Full Text] [Related]
24. A single-chain immunotoxin against carcinoembryonic antigen that suppresses growth of colorectal carcinoma cells.
Akamatsu Y; Murphy JC; Nolan KF; Thomas P; Kreitman RJ; Leung SO; Junghans RP
Clin Cancer Res; 1998 Nov; 4(11):2825-32. PubMed ID: 9829749
[TBL] [Abstract][Full Text] [Related]
25. Human adrenomedullin up-regulates interleukin-13 receptor alpha2 chain in prostate cancer in vitro and in vivo: a novel approach to sensitize prostate cancer to anticancer therapy.
Joshi BH; Leland P; Calvo A; Green JE; Puri RK
Cancer Res; 2008 Nov; 68(22):9311-7. PubMed ID: 19010904
[TBL] [Abstract][Full Text] [Related]
26. A novel combination immunotherapy for cancer by IL-13Rα2-targeted DNA vaccine and immunotoxin in murine tumor models.
Nakashima H; Terabe M; Berzofsky JA; Husain SR; Puri RK
J Immunol; 2011 Nov; 187(10):4935-46. PubMed ID: 22013118
[TBL] [Abstract][Full Text] [Related]
27. Targeting TARP, a novel breast and prostate tumor-associated antigen, with T cell receptor-like human recombinant antibodies.
Epel M; Carmi I; Soueid-Baumgarten S; Oh S; Bera T; Pastan I; Berzofsky J; Reiter Y
Eur J Immunol; 2008 Jun; 38(6):1706-20. PubMed ID: 18446790
[TBL] [Abstract][Full Text] [Related]
28. An immunotoxin with greatly reduced immunogenicity by identification and removal of B cell epitopes.
Onda M; Beers R; Xiang L; Nagata S; Wang QC; Pastan I
Proc Natl Acad Sci U S A; 2008 Aug; 105(32):11311-6. PubMed ID: 18678888
[TBL] [Abstract][Full Text] [Related]
29. HER2-specific recombinant immunotoxin 4D5scFv-PE40 passes through retrograde trafficking route and forces cells to enter apoptosis.
Sokolova E; Guryev E; Yudintsev A; Vodeneev V; Deyev S; Balalaeva I
Oncotarget; 2017 Mar; 8(13):22048-22058. PubMed ID: 28423549
[TBL] [Abstract][Full Text] [Related]
30. Characterization of B1(Fv)PE38 and B1(dsFv)PE38: single-chain and disulfide-stabilized Fv immunotoxins with increased activity that cause complete remissions of established human carcinoma xenografts in nude mice.
Benhar I; Pastan I
Clin Cancer Res; 1995 Sep; 1(9):1023-9. PubMed ID: 9816075
[TBL] [Abstract][Full Text] [Related]
31.
Chang J; Liu X; Ren H; Lu S; Li M; Zhang S; Zhao K; Li H; Zhou X; Peng L; Liu Z; Hu P
Mol Pharm; 2021 Jun; 18(6):2285-2297. PubMed ID: 33998814
[TBL] [Abstract][Full Text] [Related]
32. Immunotoxins in the treatment of refractory hairy cell leukemia.
Kreitman RJ; Pastan I
Hematol Oncol Clin North Am; 2006 Oct; 20(5):1137-51, viii. PubMed ID: 16990113
[TBL] [Abstract][Full Text] [Related]
33. Immunotoxin treatment targeted to the high-molecular-weight melanoma-associated antigen prolonging the survival of immunodeficient rats with invasive intracranial human glioblastoma multiforme.
Hjortland GO; Garman-Vik SS; Juell S; Olsen OE; Hirschberg H; Fodstad O; Engebraaten O
J Neurosurg; 2004 Feb; 100(2):320-7. PubMed ID: 15086240
[TBL] [Abstract][Full Text] [Related]
34. In vitro and in vivo studies of antitumor effects of the recombinant immunotoxin MSH-PE38KDEL on melanoma.
Hui Q; Ma J; Song J; Liu Z; Ren H; Jiang W; Wang Y; Xu Y; Guo D; Zhang X; Lu S
Neoplasma; 2014; 61(4):392-400. PubMed ID: 25027740
[TBL] [Abstract][Full Text] [Related]
35. Targeted therapy of carcinomas using BR96 sFv-PE40, a single-chain immunotoxin that binds to the Le(y) antigen.
Siegall CB
Semin Cancer Biol; 1995 Oct; 6(5):289-95. PubMed ID: 8562906
[TBL] [Abstract][Full Text] [Related]
36. In vitro and in vivo characterization of BR96 sFv-PE40. A single-chain immunotoxin fusion protein that cures human breast carcinoma xenografts in athymic mice and rats.
Siegall CB; Chace D; Mixan B; Garrigues U; Wan H; Paul L; Wolff E; Hellström I; Hellström KE
J Immunol; 1994 Mar; 152(5):2377-84. PubMed ID: 8133048
[TBL] [Abstract][Full Text] [Related]
37. Interleukin-4 receptor cytotoxin as therapy for human malignant pleural mesothelioma xenografts.
Beseth BD; Cameron RB; Leland P; You L; Varricchio F; Kreitman RJ; Maki RA; Jablons DM; Husain SR; Puri RK
Ann Thorac Surg; 2004 Aug; 78(2):436-43; discussion 436-43. PubMed ID: 15276492
[TBL] [Abstract][Full Text] [Related]
38. Anti-Tac(Fab)-PE40, a recombinant double-chain immunotoxin which kills interleukin-2-receptor-bearing cells and induces complete remission in an in vivo tumor model.
Kreitman RJ; Chang CN; Hudson DV; Queen C; Bailon P; Pastan I
Int J Cancer; 1994 Jun; 57(6):856-64. PubMed ID: 8206679
[TBL] [Abstract][Full Text] [Related]
39. Monovalent immunotoxin containing truncated form of Pseudomonas exotoxin as potent antitumor agent.
Debinski W; Pastan I
Cancer Res; 1992 Oct; 52(19):5379-85. PubMed ID: 1394141
[TBL] [Abstract][Full Text] [Related]
40. Construction, expression, and characterization of an anti-tumor immunotoxin containing the human anti-c-Met single-chain antibody and PE38KDEL.
Liu Z; Feng Z; Zhu X; Xu W; Zhu J; Zhang X; Fan Z; Ji G
Immunol Lett; 2013 Jan; 149(1-2):30-40. PubMed ID: 23026237
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
